CD20 Antibody Primes B Lymphocytes for Type I Interferon Production

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Xu, Dongsheng ^a,c   Staedman, Andrew ^b   Zhang, Luwen ^a,b  

^a UNIVERSITY OF NEBRASKA   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD20 ANTIBODY; CD20 ANTIGEN; INTERFERON; RIBONUCLEASE; RITUXIMAB; TOLL LIKE RECEPTOR 7;

ARTICLE; B LYMPHOCYTE; CELL LINEAGE; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG POTENTIATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; PLASMID; PROTEIN EXPRESSION; RNA EXTRACTION; SENDAI VIRUS; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; TIME FACTORS;

EID: 84879158239     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067900     Document Type: Article

References (57)

1. Samuel CE, (2001) Antiviral actions of interferons. Clin Microbiol Rev 14: 778-809, table of contents. doi:10.1128/CMR.14.4.778-809.2001. PubMed: 11585785.
2. Sen GC, (2001) Viruses and Interferons. Annu Rev Microbiol 55: 255-281. doi:10.1146/annurev.micro.55.1.255. PubMed: 11544356.
3. Baechler EC, Gregersen PK, Behrens TW, (2004) The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 16: 801-807. doi:10.1016/j.coi.2004.09.014. PubMed: 15511676.
4. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, et al. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100: 2610-2615. doi:10.1073/pnas.0337679100. PubMed: 12604793.
5. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, et al. (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197: 711-723. doi:10.1084/jem.20021553. PubMed: 12642603.
6. DeStefano E, Friedman RM, Friedman-Kien AE, Goedert JJ, Henriksen D, et al. (1982) Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. J Infect Dis 146: 451-459. doi:10.1093/infdis/146.4.451. PubMed: 7119475.
7. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J, (1982) Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 216: 429-431. doi:10.1126/science.6176024. PubMed: 6176024.
8. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, et al. (2000) Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9: 664-671. doi:10.1191/096120300674499064. PubMed: 11199920.
9. Rönnblom LE, Alm GV, Oberg K, (1991) Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 30: 537-540. doi:10.3109/02841869109092414. PubMed: 1854511.
10. Kälkner KM, Rönnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, et al. (1998) Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 91: 393-399. doi:10.1093/qjmed/91.6.393. PubMed: 9709457.
11. Kono DH, Baccala R, Theofilopoulos AN, (2003) Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor. Autoimmunity 36: 503-510. doi:10.1080/08916930310001624665. PubMed: 14984027.
12. Banchereau J, Pascual V, Palucka AK, (2004) Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20: 539-550. doi:10.1016/S1074-7613(04)00108-6. PubMed: 15142523.
13. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, et al. (2005) RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 202: 1171-1177. doi:10.1084/jem.20050630. PubMed: 16260486.
14. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ, (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8: 140-174. PubMed: 15564720.
15. Riley JK, Sliwkowski MX, (2000) CD20: a gene in search of a function. Semin Oncol 27: 17-24. PubMed: 11225995.
16. Janas E, Priest R, Malhotra R, (2005) Functional role of lipid rafts in CD20 activity? Biochem Soc Symp: pp. 165-175. PubMed: 15649140.
17. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, et al. (2010) CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 120: 214-222. doi:10.1172/JCI40231. PubMed: 20038800.
18. Grillo-López AJ, (2000) Rituximab: an insider's historical perspective. Semin Oncol 27: 9-16. PubMed: 11226006.
19. Pescovitz MD, (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6: 859-866. doi:10.1111/j.1600-6143.2006.01288.x. PubMed: 16611321.
20. Lambotte O, Dürbach A, Kotb R, Ferlicot S, Delfraissy JF, et al. (2005) Failure of rituximab to treat a lupus flare-up with nephritis. Clin Nephrol 64: 73-77. PubMed: 16047649.
21. Shishkin P, (2008) Wider Aim for Rituxan Fails. Wall Street Journal: pp. 30.
22. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, et al. (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62: 222-233. doi:10.1002/art.27233. PubMed: 20039413.
23. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, et al. (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 1215-1226. doi:10.1002/art.34359. PubMed: 22231479.
24. Lightstone L, (2012) The landscape after LUNAR: rituximab's crater-filled path. Arthritis Rheum 64: 962-965. doi:10.1002/art.34362. PubMed: 22231618.
25. Kirou KA, Gkrouzman E, Chevalier JM, Seshan SV, (2012) Antiinflammatory strategies, not just B cell depletion, are required for optimal therapy for severe proliferative lupus nephritis: comment on the article by Rovin et al. Arthritis Rheum 64: 3486; author reply 3486. doi:10.1002/art.34616. PubMed: 22777724.
26. Pascual V, Banchereau J, Palucka AK, (2003) The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol 15: 548-556. doi:10.1097/00002281-200309000-00005. PubMed: 12960479.
27. Crow MK, (2003) Interferon-alpha: a new target for therapy in systemic lupus erythematosus? Arthritis Rheum 48: 2396-2401. doi:10.1002/art.11226. PubMed: 13130457.
28. Rönnblom L, Alm GV, (2001) An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 22: 427-431. doi:10.1016/S1471-4906(01)01955-X. PubMed: 11473831.
29. Jiang Y, Xu D, Zhao Y, Zhang L, (2008) Mutual Inhibition between Kaposi's Sarcoma-Associated Herpesvirus and Epstein-Barr Virus Lytic Replication Initiators in Dually-Infected Primary Effusion Lymphoma. PLOS ONE 3: e1569.
30. Xu D, Coleman T, Zhang J, Fagot A, Kotalik C, et al. (2007) Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. J Virol 81: 6068-6078. doi:10.1128/JVI.02743-06. PubMed: 17376914.
31. Xu Y, AuCoin DP, Huete AR, Cei SA, Hanson LJ, et al. (2005) A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication. J Virol 79: 3479-3487. doi:10.1128/JVI.79.6.3479-3487.2005. PubMed: 15731242.
32. Zhang L, (2000) Gradient temperature hybridization using a thermocycler for RNase protection assays. Mol Biotechnol 14: 73-75. doi:10.1385/MB:14:1:73. PubMed: 10911616.
33. Carter KL, Cahir-McFarland E, Kieff E, (2002) Epstein-barr virus-induced changes in B-lymphocyte gene expression. J Virol 76: 10427-10436. doi:10.1128/JVI.76.20.10427-10436.2002. PubMed: 12239319.
34. Henderson A, Ripley S, Heller M, Kieff E, (1983) Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. Proc Natl Acad Sci U S A 80: 1987-1991. doi:10.1073/pnas.80.7.1987. PubMed: 6300885.
35. Hurley EA, Klaman LD, Agger S, Lawrence JB, Thorley-Lawson DA, (1991) The prototypical Epstein-Barr virus-transformed lymphoblastoid cell line IB4 is an unusual variant containing integrated but no episomal viral DNA. J Virol 65: 3958-3963. PubMed: 1645805.
36. Cahir McFarland, ED, Izumi KM, Mosialos G (1999) Barr: Epstein virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. Oncogene 18: 6959-6964.
37. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E, (2000) NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A 97: 6055-6060. doi:10.1073/pnas.100119497. PubMed: 10811897.
38. Frost V, Delikat S, Al-Mehairi S, Sinclair AJ, (2001) Regulation of p27KIP1 in Epstein-Barr virus-immortalized lymphoblastoid cell lines involves non-apoptotic caspase cleavage. J Gen Virol 82: 3057-3066. PubMed: 11714984.
39. Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, et al. (2003) CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 63: 5480-5489. PubMed: 14500384.
40. Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY, (2000) Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 60: 7170-7176. PubMed: 11156427.
41. Janas E, Priest R, Wilde JI, White JH, Malhotra R, (2005) Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 139: 439-446. doi:10.1111/j.1365-2249.2005.02720.x. PubMed: 15730389.
42. Roberts RM, Liu L, Guo Q, Leaman D, Bixby J, (1998) The evolution of the type I interferons. J Interferon Cytokine Res 18: 805-816. doi:10.1089/jir.1998.18.805. PubMed: 9809615.
43. Deans JP, Li H, Polyak MJ, (2002) CD20-mediated apoptosis: signalling through lipid rafts. Immunology 107: 176-182. doi:10.1046/j.1365-2567.2002.01495.x. PubMed: 12383196.
44. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, et al. (2004) Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 101: 5598-5603. doi:10.1073/pnas.0400937101. PubMed: 15034168.
45. Xuan C, Steward KK, Timmerman JM, Morrison SL, (2010) Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 115: 2864-2871. doi:10.1182/blood-2009-10-250555. PubMed: 20139095.
46. Davis TA, Maloney DG, Grillo-López AJ, White CA, Williams ME, et al. (2000) Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 6: 2644-2652. PubMed: 10914705.
47. Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, et al. (2008) Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group, Leuk Lymphoma 49: 102-112.
48. Vosslamber S, Raterman HG, van der Pouw Kraan TC, Schreurs MW, von Blomberg BM, et al. (2011) Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis 70: 1153-1159. doi:10.1136/ard.2010.147199. PubMed: 21444302.
49. Verweij CL, Vosslamber S, (2011) New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine. Discov Med 12: 229-236. PubMed: 21955850.
50. Nanda S, (2011) Rheumatoid arthritis: rituximab-induced changes in type 1 IFN response correlate with outcome. Nat Rev Rheumatol 7: 253. doi:10.1038/nrrheum.2011.45. PubMed: 21532635.
51. Valente RM, Ehlers E, Xu D, Ahmad H, Steadman A, et al. (2012) Toll-like receptor 7 stimulates the expression of Epstein-Barr virus latent membrane protein 1. PLOS ONE 7: e43317. doi:10.1371/journal.pone.0043317. PubMed: 22952664.
52. Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, et al. (2004) Mouse CD20 expression and function. Int Immunol 16: 119-129. doi:10.1093/intimm/dxh009. PubMed: 14688067.
53. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF, (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 121: 1121-1132. doi:10.1083/jcb.121.5.1121. PubMed: 7684739.
54. Moon UY, Park SJ, Oh ST, Kim WU, Park SH, et al. (2004) Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther 6: R295-R302. doi:10.1186/ar1181. PubMed: 15225364.
55. Yu SF, Wu HC, Tsai WC, Yen JH, Chiang W, et al. (2005) Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. Med Microbiol Immunol 194: 115-120. doi:10.1007/s00430-004-0230-5. PubMed: 15378356.
56. Treschow AP, Teige I, Nandakumar KS, Holmdahl R, Issazadeh-Navikas S, (2005) Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice. Arthritis Rheum 52: 3739-3748. doi:10.1002/art.21496. PubMed: 16320324.
57. de Hooge AS, van de Loo FA, Koenders MI, Bennink MB, Arntz OJ, et al. (2004) Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice. Arthritis Rheum 50: 2014-2023. doi:10.1002/art.20302. PubMed: 15188379.